A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC
Phase
PHASE1, PHASE2
Enrollment
160 (est.)
Age range
18 Years to —
Sex
ALL
Summary
The goal of this trial is to learn about the safety and recommended dose of TRI-611 in adults with ALK-positive non-small cell lung cancer (NSCLC), and to evaluate its antitumor activity. The study runs in two parts: a dose-finding part and an expansion part across three groups defined by prior therapy.
Conditions studied
Sign-up window
Mar 11, 2026 – est. completion May 31, 2029
Sponsors
Study locations
University of Colorado Cancer Center
Aurora, Colorado
Washington University Medical Center
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
Taylor Cancer Research Center
Maumee, Ohio
SCRI Oncology Partners
Nashville, Tennessee
START Mountain Region
West Valley City, Utah
NEXT Virginia
Fairfax, Virginia